Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > Highly undervalued!!!

<< Previous

Bullboard Posts

Next >>

Comment by LFC1973on Dec 08, 2020 7:26am

306 Views

Post# 32056180

RE:RE:RE:RE:Highly undervalued!!!

Hi Eprint,

See below:

CONSOLIDATION UPDATE

Further to the approval of the 20 for 1 Common Share consolidation (the “Consolidation”) that was approved at the annual general and special meeting of shareholders of Hemostemix held on May 6, 2020‎, Hemostemix ‎intends to implement the Consolidation prior to December 31, 2020. Hemostemix will provide further information in ‎respect of the Consolidation in future news releases when the board of directors of Hemostemix has made a decision in ‎respect of the effective date of the Consolidation.‎

<< Previous

Bullboard Posts

Next >>

BioNTech & Cardiol Therapeutics – on the verge of a breakout